Stockscreener 앱 받기
9.71
0.31%
0.03
시간 외 거래:
9.71
전일 마감가:
$9.68
열려 있는:
$9.36
하루 거래량:
582.25K
Relative Volume:
1.28
시가총액:
$1.30B
수익:
$53.99M
순이익/손실:
$-222.30M
주가수익비율:
-5.3452
EPS:
-1.8166
순현금흐름:
$-213.50M
1주 성능:
+3.19%
1개월 성능:
-5.73%
6개월 성능:
+44.93%
1년 성능:
+80.82%
1일 변동 폭
$9.36
$9.76
1주일 범위
$9.13
$10.29
52주 변동 폭
$3.30
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
9.71 | 1.30B | 53.99M | -222.30M | -213.50M | -1.8166 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-05-28 | 개시 | Deutsche Bank | Buy |
| 2024-10-07 | 개시 | Piper Sandler | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2020-11-20 | 개시 | BofA Securities | Buy |
| 2020-09-22 | 개시 | Goldman | Buy |
| 2020-07-27 | 개시 | SVB Leerink | Outperform |
| 2020-07-24 | 개시 | Jefferies | Buy |
모두보기
Immatics N V 주식(IMTX)의 최신 뉴스
Immatics NV (IMTX) seeing strong enrollment in a key phase 3 trial of drug candidate - MSN
Immatics (IMTX) Expected to Announce Earnings on Thursday - MarketBeat
Immatics (IMTX) Chief Development Officer files Form 3 detailing equity - Stock Titan
Immatics (IMTX) CMO Cedrik Britten reports option, RSU and share holdings - Stock Titan
Immatics General Counsel reports option and RSU holdings | IMTX SEC FilingForm 3 - Stock Titan
[Form 3] Immatics N.V. Initial Statement of Beneficial Ownership - Stock Titan
Immatics (IMTX) CEO reports options, RSUs and share holdings - Stock Titan
Immatics (IMTX) director reports sizeable stock option holdings - Stock Titan
Immatics (IMTX) CFO reports 350,000 stock options holding - Stock Titan
Immatics N.V. (IMTX) director Eliot Forster details stock option holdings - Stock Titan
Immatics (IMTX) Chief People Officer reports 211,000 share options on Form 3 - Stock Titan
Immatics (IMTX) director discloses existing stock option grants - Stock Titan
Immatics (IMTX) director discloses multiple long-dated stock options - Stock Titan
Immatics (IMTX) director reports multiple long-dated stock option grants - Stock Titan
Immatics (IMTX) COO details stock options, RSUs and share holdings - Stock Titan
Immatics (IMTX) CBO details stock option and RSU positions - Stock Titan
Immatics (IMTX) director Chambre details ordinary share and option stakes - Stock Titan
Immatics (IMTX) director Michael G. Atieh reports stock option positions - Stock Titan
Immatics (IMTX) Chief Innovation Officer discloses option and RSU stakes - Stock Titan
Immatics (IMTX) director entities disclose indirect share and option stakes - Stock Titan
Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX) - MSN
Aug PreEarnings: What is the target price for Immatics NV stockWeekly Trading Summary & Verified Technical Signals - baoquankhu1.vn
Risk Check: Is Immatics NV a defensive stock2026 Winners & Losers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Immatics NV Stock (ISIN: NL0015255052) Advances on Promising TCR-T Therapy Data Amid Biotech Sector - AD HOC NEWS
Why Immatics (IMTX) Is Down 6.4% After Deepening Losses And Highlighting SUPRAME Phase 3 Progress - simplywall.st
Immatics N.V. (IMTX) director Hothum discloses options and indirect shares - Stock Titan
IMTX: Jefferies Analyst Biren Amin Rates Immatics with a "Buy" and Sets Price Target at $18.00 | IMTX Stock News - GuruFocus
Immatics (NASDAQ:IMTX) Stock Price Up 9.3%Here's What Happened - MarketBeat
Immatics (NASDAQ:IMTX) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside - Yahoo Finance
Immatics N.V. $IMTX Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Immatics NV Stock (ISIN: NL0015255052) Holds Steady Amid Biotech Sector Volatility - AD HOC NEWS
(IMTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate - Insider Monkey
Can Immatics NV Equity Warrant generate free cash flow2026 Market Sentiment & Target Return Focused Stock Picks - baoquankhu1.vn
Immatics (NASDAQ:IMTX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Immatics (NASDAQ:IMTX) Shares Gap DownTime to Sell? - MarketBeat
Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)? - simplywall.st
Jefferies Financial Group Inc. Takes $10.18 Million Position in Immatics N.V. $IMTX - MarketBeat
Insider Buy: What is the target price for Immatics NV stockDay Trade & Real-Time Volume Triggers - baoquankhu1.vn
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to "Hold" - MarketBeat
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to “Hold” - Defense World
Is Immatics N.V. Equity Warrant stock near bottom after declineGold Moves & Low Risk Growth Stock Ideas - Naître et grandir
Tech Rally: Should I invest in Immatics NV Equity Warrant before earnings2025 Momentum Check & Short-Term Swing Trade Alerts - baoquankhu1.vn
Immatics 2025 Financial Results: Q4 Revenue $23M, Annual Loss $222.2MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Immatics (NASDAQ:IMTX) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Immatics Earnings Report: Q4 Overview - Sahm
Immatics Announces Full Year 2025 Financial Results and Business Update - Investing News Network
Immatics: Fourth Quarter Financial Overview - Bitget
Immatics N V (IMTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):